1312 related articles for article (PubMed ID: 17311302)
1. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
[TBL] [Abstract][Full Text] [Related]
3. The IARC TP53 database: new online mutation analysis and recommendations to users.
Olivier M; Eeles R; Hollstein M; Khan MA; Harris CC; Hainaut P
Hum Mutat; 2002 Jun; 19(6):607-14. PubMed ID: 12007217
[TBL] [Abstract][Full Text] [Related]
4. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
5. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations.
Soussi T; Kato S; Levy PP; Ishioka C
Hum Mutat; 2005 Jan; 25(1):6-17. PubMed ID: 15580553
[TBL] [Abstract][Full Text] [Related]
6. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
7. The UMD TP53 database and website: update and revisions.
Hamroun D; Kato S; Ishioka C; Claustres M; Béroud C; Soussi T
Hum Mutat; 2006 Jan; 27(1):14-20. PubMed ID: 16278824
[TBL] [Abstract][Full Text] [Related]
8. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
[TBL] [Abstract][Full Text] [Related]
9. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations.
Mathe E; Olivier M; Kato S; Ishioka C; Vaisman I; Hainaut P
Hum Mutat; 2006 Feb; 27(2):163-72. PubMed ID: 16395672
[TBL] [Abstract][Full Text] [Related]
10. The UMD-p53 database: new mutations and analysis tools.
Béroud C; Soussi T
Hum Mutat; 2003 Mar; 21(3):176-81. PubMed ID: 12619103
[TBL] [Abstract][Full Text] [Related]
11. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
12. p53 from basic research to clinical applications.
Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
[TBL] [Abstract][Full Text] [Related]
13. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
14. Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53.
Gorlov IP; Gorlova OY; Amos CI
Hum Mutat; 2005 Nov; 26(5):446-54. PubMed ID: 16173033
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
[TBL] [Abstract][Full Text] [Related]
16. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
[TBL] [Abstract][Full Text] [Related]
17. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer.
Hernandez-Boussard T; Rodriguez-Tome P; Montesano R; Hainaut P
Hum Mutat; 1999; 14(1):1-8. PubMed ID: 10447253
[TBL] [Abstract][Full Text] [Related]
18. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
19. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection.
Soussi T; Asselain B; Hamroun D; Kato S; Ishioka C; Claustres M; Béroud C
Clin Cancer Res; 2006 Jan; 12(1):62-9. PubMed ID: 16397025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
